human pct  (R&D Systems)

Journal: Nature communications

Article Title: Hyperphosphorylated PTEN exerts oncogenic properties.

doi: 10.1038/s41467-023-38740-x

Figure Lengend Snippet: Fig. 2 | Tumor protection in PtenS380A/A and PtenΔ4/Δ4 mice despite AKT signaling. a Overall and (b) tumor-specific incidence of tumors at 9 months in FVB mice of indicated genotypes. Number of mice (n) for (a–c) is indicated in (a). Incidence of specific tumorsis basedon macroscopic screening. “Other tumors” include lipomas and tumors in breast, uterus and liver. Photos above graph show examples of below graphed tumors. c Incidence at 9 months of lymphadenopathy. We note that the incidence in +/+ was 0%. Photo depicts an example of lymphadenopathy in a sub- mandibular lymph node of a Pten+/– mouse. d, e As (a, b) but now at 16 months,

Article Snippet: In vitro protein binding studies were conducted in 100 μl PBS at RT using recombinant human PTEN (R&D systems Cat. #847-PN) and recombinant human β-catenin (Sino Biological Cat. #11279-H20B).

Techniques:

Journal: Nature communications

Article Title: Hyperphosphorylated PTEN exerts oncogenic properties.

doi: 10.1038/s41467-023-38740-x

Figure Lengend Snippet: Fig. 3 | PtenHNP/HNP males have a less advanced PIN phenotype than Pten+/– males despite similarly reduced PTEN levels. a CRISPR-CAS9-targeting design of Pten hypomorphic mice. PtenHN, hypomorph Neo; PtenHNP, hypomorph Neo & PolyA. b WB of prostate lysates harvested at 2 months, probed for PTEN and activation of AKT signaling pathway. Blot is representative of at least 3 individual samples. Ponceau S (PonS) staining served as loading control. c Quantitation of PTEN level in

Article Snippet: In vitro protein binding studies were conducted in 100 μl PBS at RT using recombinant human PTEN (R&D systems Cat. #847-PN) and recombinant human β-catenin (Sino Biological Cat. #11279-H20B).

Techniques: CRISPR, Activation Assay, Staining, Control, Quantitation Assay

Journal: Nature communications

Article Title: Hyperphosphorylated PTEN exerts oncogenic properties.

doi: 10.1038/s41467-023-38740-x

Figure Lengend Snippet: Fig. 4 | PIN lesion formation in Pten+/– males is characterized by loss of PTEN catalytic function. a Immunostaining of consecutive sections of normal and PIN lesion (*) tubules of indicated genotypes stained for H&E, PTEN and P-AKTS473. Scale bar is 100 µm. b Close-up of a small lesion of epithelial cells that have lost PTEN expression and have gained P-AKTS473 expression. c Quantitation of PIN lesions with increase in P-AKTS473 expression and simultaneous loss of PTEN. 5 mice per geno- type with 12-55 PIN lesions per mouse were analyzed by IF staining. Data are

Article Snippet: In vitro protein binding studies were conducted in 100 μl PBS at RT using recombinant human PTEN (R&D systems Cat. #847-PN) and recombinant human β-catenin (Sino Biological Cat. #11279-H20B).

Techniques: Immunostaining, Staining, Expressing, Quantitation Assay

Journal: Nature communications

Article Title: Hyperphosphorylated PTEN exerts oncogenic properties.

doi: 10.1038/s41467-023-38740-x

Figure Lengend Snippet: Fig. 7 | Hyperactive WNT signaling predisposes PtenS380D mice to PIN lesions. a Mixtures of recombinant human PTEN and β−catenin proteins subjected to immunoprecipitation with PTEN or corresponding control (anti-RFP) antibodies and analyzed by immunoblotting using PTEN and β−catenin antibodies.The blot is representative of 3 independent experiments. b Immunoblot of 2-month-old frac- tionated prostate lysates of indicated genotypes subjected to immunoprecipitation with PTEN or control antibody and analyzed with the indicated antibodies. Blots represent 3 independent experiments. * Marks IgG band, only visible in the nuclear fraction because of the necessary long exposure to be able to detectthe PTEN band.

Article Snippet: In vitro protein binding studies were conducted in 100 μl PBS at RT using recombinant human PTEN (R&D systems Cat. #847-PN) and recombinant human β-catenin (Sino Biological Cat. #11279-H20B).

Techniques: Recombinant, Immunoprecipitation, Control, Western Blot